TISIDB

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Apical cell membrane. Cell projection, lamellipodium. Cell projection, filopodium. Cell projection, ruffle. Cell projection, microvillus Membrane raft Membrane Single-pass type I membrane protein Note=In single attached epithelial cells is restricted to a preapical pole on the free plasma membrane whereas other apical and basolateral proteins are not yet polarized. Colocalizes with SLC9A3R2 at the apical plasma membrane during epithelial polarization. Colocalizes with SLC9A3R1 at the trans-Golgi network (transiently) and at the apical plasma membrane. Its association with the membrane raft is transient. Colocalizes with actin filaments, EZR and SLC9A3R1 in a punctate pattern at the apical cell surface where microvilli form. Colocalizes with EZR and SLC9A3R2 at the apical cell membrane of glomerular epithelium cells (By similarity). Forms granular, punctuated pattern, forming patches, preferentially adopting a polar distribution, located on the migrating poles of the cell or forming clusters along the terminal ends of filipodia establishing contact with the endothelial cells. Colocalizes with the submembrane actin of lamellipodia, particularly associated with ruffles. Colocalizes with vinculin at protrusions of cells. Colocalizes with ITGB1. Colocalizes with PARD3, PRKCI, EXOC5, OCLN, RAB11A and RAB8A in apical membrane initiation sites (AMIS) during the generation of apical surface and luminogenesis (By similarity).
Domain	PF06365 CD34/Podocalyxin family
Function	Involved in the regulation of both adhesion and cell morphology and cancer progression. Function as an anti-adhesive molecule that maintains an open filtration pathway between neighboring foot processes in the podocyte by charge repulsion. Acts as a pro-adhesive molecule, enhancing the adherence of cells to immobilized ligands, increasing the rate of migration and cell-cell contacts in an integrin-dependent manner. Induces the formation of apical actin-dependent microvilli. Involved in the formation of a preapical plasma membrane subdomain to set up initial epithelial polarization and the apical lumen formation during renal tubulogenesis. Plays a role in cancer development and aggressiveness by inducing cell migration and invasion through its interaction with the actin-binding protein EZR. Affects EZR-dependent signaling events, leading to increased activities of the MAPK and PI3K pathways in cancer cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001822 kidney development GO:0002064 epithelial cell development GO:0007162 negative regulation of cell adhesion GO:0022407 regulation of cell-cell adhesion GO:0022408 negative regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030031 cell projection assembly GO:0030033 microvillus assembly GO:0030335 positive regulation of cell migration GO:0032528 microvillus organization GO:0032530 regulation of microvillus organization GO:0032534 regulation of microvillus assembly GO:0032835 glomerulus development GO:0033627 cell adhesion mediated by integrin GO:0033628 regulation of cell adhesion mediated by integrin GO:0033630 positive regulation of cell adhesion mediated by integrin GO:0033631 cell-cell adhesion mediated by integrin GO:0033632 regulation of cell-cell adhesion mediated by integrin GO:0033634 positive regulation of cell-cell adhesion mediated by integrin GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0035850 epithelial cell differentiation involved in kidney development GO:0040017 positive regulation of locomotion GO:0045785 positive regulation of cell adhesion GO:0050900 leukocyte migration GO:0051272 positive regulation of cellular component movement GO:0060491 regulation of cell projection assembly GO:0060562 epithelial tube morphogenesis GO:0061005 cell differentiation involved in kidney development GO:0061318 renal filtration cell differentiation GO:0072001 renal system development GO:0072006 nephron development GO:0072009 nephron epithelium development GO:0072010 glomerular epithelium development GO:0072015 glomerular visceral epithelial cell development GO:0072073 kidney epithelium development GO:0072112 glomerular visceral epithelial cell differentiation GO:0072175 epithelial tube formation GO:0072310 glomerular epithelial cell development GO:0072311 glomerular epithelial cell differentiation GO:2000147 positive regulation of cell motility
Molecular Function	-
Cellular Component	GO:0001726 ruffle GO:0005902 microvillus GO:0016324 apical plasma membrane GO:0030027 lamellipodium GO:0030175 filopodium GO:0031252 cell leading edge GO:0031253 cell projection membrane GO:0031528 microvillus membrane GO:0036056 filtration diaphragm GO:0036057 slit diaphragm GO:0044297 cell body GO:0045121 membrane raft GO:0045177 apical part of cell GO:0098589 membrane region GO:0098857 membrane microdomain GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PODXL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PODXL in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PODXL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.944	0.032
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.833	0.61
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.019	0.37
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.664	0.0177
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.567	0.781
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.784	0.753
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.722	0.169
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.657	0.678
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.812	0.641
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.299	0.477
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.727	0.285
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.279	0.0123

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PODXL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	11.8	-11.8	0.193
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	18.2	-18.2	0.199
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PODXL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PODXL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PODXL. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PODXL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PODXL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PODXL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PODXL
Name	podocalyxin-like
Aliases	PCLP; Gp200; PCLP-1; GCTM-2 antigen; podocalyxin-like protein 1; Podocalyxin
Chromosomal Location	7q32-q33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PODXL collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PODXL